Christina Kazzi, Ty Simpson, Cassandra Abbott, Miriam Wronski, Nabil Seery, Tracie Huey-Lin Tan, Robb Wesselingh, Katherine Ko, Shu Min Wong, Shafqat Inam, Constantine Tam, Shaun Fleming, Terence J O'Brien, Rubina Alpitsis, Andrew Spencer, Charles Malpas, Mastura Monif
{"title":"使用改良的免疫效应细胞相关脑病（ICE）评分监测嵌合抗原受体（CAR） t细胞治疗对感觉和身体损伤和非母语背景患者的神经系统并发症：一个病例系列。","authors":"Christina Kazzi, Ty Simpson, Cassandra Abbott, Miriam Wronski, Nabil Seery, Tracie Huey-Lin Tan, Robb Wesselingh, Katherine Ko, Shu Min Wong, Shafqat Inam, Constantine Tam, Shaun Fleming, Terence J O'Brien, Rubina Alpitsis, Andrew Spencer, Charles Malpas, Mastura Monif","doi":"10.1136/bmjno-2024-000927","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Immune effector cell-associated neurotoxicity syndrome (ICANS) is a common complication of chimeric antigen receptor (CAR) T-cell therapy. Current practice guidelines recommend the immune effector cell-associated encephalopathy (ICE) score for the assessment and monitoring of ICANS.</p><p><strong>Objective: </strong>To demonstrate modifications to ICE score to patients with vision and hearing impairments or who are who are from non-native-speaking backgrounds.</p><p><strong>Methods: </strong>We discuss five cases and the modifications made to adapt the ICE score to meet patients' needs.</p><p><strong>Results: </strong>Modifications to ICE score was feasible and it assisted with CAR T cell therapy outcome monitoring.</p><p><strong>Discussion: </strong>These cases highlight the need for flexible and patient-tailored strategies and the importance of collaboration between multidisciplinary teams and patients' families/caregivers when monitoring patients for ICANS after CAR T-cell therapy.</p>","PeriodicalId":52754,"journal":{"name":"BMJ Neurology Open","volume":"7 1","pages":"e000927"},"PeriodicalIF":2.4000,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11822436/pdf/","citationCount":"0","resultStr":"{\"title\":\"Monitoring the neurological complications of chimeric antigen receptor (CAR) T-cell therapy in patients with sensory and physical impairments and non-native-speaking backgrounds using modified immune effector cell-associated encephalopathy (ICE) scores: a case series.\",\"authors\":\"Christina Kazzi, Ty Simpson, Cassandra Abbott, Miriam Wronski, Nabil Seery, Tracie Huey-Lin Tan, Robb Wesselingh, Katherine Ko, Shu Min Wong, Shafqat Inam, Constantine Tam, Shaun Fleming, Terence J O'Brien, Rubina Alpitsis, Andrew Spencer, Charles Malpas, Mastura Monif\",\"doi\":\"10.1136/bmjno-2024-000927\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Immune effector cell-associated neurotoxicity syndrome (ICANS) is a common complication of chimeric antigen receptor (CAR) T-cell therapy. Current practice guidelines recommend the immune effector cell-associated encephalopathy (ICE) score for the assessment and monitoring of ICANS.</p><p><strong>Objective: </strong>To demonstrate modifications to ICE score to patients with vision and hearing impairments or who are who are from non-native-speaking backgrounds.</p><p><strong>Methods: </strong>We discuss five cases and the modifications made to adapt the ICE score to meet patients' needs.</p><p><strong>Results: </strong>Modifications to ICE score was feasible and it assisted with CAR T cell therapy outcome monitoring.</p><p><strong>Discussion: </strong>These cases highlight the need for flexible and patient-tailored strategies and the importance of collaboration between multidisciplinary teams and patients' families/caregivers when monitoring patients for ICANS after CAR T-cell therapy.</p>\",\"PeriodicalId\":52754,\"journal\":{\"name\":\"BMJ Neurology Open\",\"volume\":\"7 1\",\"pages\":\"e000927\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2025-02-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11822436/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMJ Neurology Open\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/bmjno-2024-000927\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ Neurology Open","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/bmjno-2024-000927","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Monitoring the neurological complications of chimeric antigen receptor (CAR) T-cell therapy in patients with sensory and physical impairments and non-native-speaking backgrounds using modified immune effector cell-associated encephalopathy (ICE) scores: a case series.
Background: Immune effector cell-associated neurotoxicity syndrome (ICANS) is a common complication of chimeric antigen receptor (CAR) T-cell therapy. Current practice guidelines recommend the immune effector cell-associated encephalopathy (ICE) score for the assessment and monitoring of ICANS.
Objective: To demonstrate modifications to ICE score to patients with vision and hearing impairments or who are who are from non-native-speaking backgrounds.
Methods: We discuss five cases and the modifications made to adapt the ICE score to meet patients' needs.
Results: Modifications to ICE score was feasible and it assisted with CAR T cell therapy outcome monitoring.
Discussion: These cases highlight the need for flexible and patient-tailored strategies and the importance of collaboration between multidisciplinary teams and patients' families/caregivers when monitoring patients for ICANS after CAR T-cell therapy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
